Oppenheimer Maintains Bullish View on Sarepta (SRPT) Despite Sell-Off on FDA Briefing Documents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky weekÂ
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 17.58 -0.6 (3.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.18 | 52 Week High | $63.73 | |||
| Open | $17.94 | 52 Week Low | $8.00 | |||
| Day High | $18.12 | P/E | N/A | |||
| Day Low | $17.16 | EPS | $-5.69 | |||
| Volume | 607,103 | |||||
